MannKind is trading 5.2% down today at $3.90, tracking a sharp pullback in the broader biotechnology sector.
- The decline appears driven by risk-off sentiment rather than company-specific developments, as the XBI biotech ETF dropped over 3%.
- Shares are giving back a portion of yesterday’s strong rally; there are no fresh earnings, FDA actions, or major analyst calls reported today.